Form 4: Lyell Immunopharma CSO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold 1,671 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL), reported a transaction on February 11, 2026.
• He sold 1,671 shares of Lyell Immunopharma common stock.
• The shares were sold at a weighted average price of $23.39 per share, with prices ranging from $23.3939 to $24.6305.
• The sale was an automatic transaction to cover tax withholding obligations arising from the settlement of performance-based vested restricted stock units.
• Following this transaction, Mr. Lee directly beneficially owns 16,938 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was explicitly for tax withholding purposes related to vested equity, a common occurrence for executives.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations are common and typically not indicative of a change in management's outlook on the company's future performance. This is a routine event for executives receiving equity compensation.

Stakeholder Impact

• Shareholders may note the sale, but its tax-related nature suggests minimal direct impact on their investment decisions based solely on this transaction.

Key Dates

Recommendation

The sale of shares by the Chief Scientific Officer was explicitly stated to cover tax withholding obligations from vested restricted stock units. This is a routine, non-discretionary transaction for executives and does not reflect a change in the insider's confidence in the company's prospects. Therefore, it does not provide a basis for altering an investment recommendation.

Keywords

Lyell Immunopharma, LYEL, Form 4, insider trading, stock sale, executive compensation, tax withholding, Gary K. Lee, Chief Scientific Officer